Navigation Links
Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013
Date:11/30/2009

WALTHAM, Mass., Nov. 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the hepatitis C virus drug market in Russia will grow nine percent annually over the 2008 - 2013 study period, reaching $327 million by 2013. This growth will be driven mainly by increased government spending on healthcare and increased use of more-expensive therapies like pegylated interferons [peg-IFNs] (i.e., Roche's Pegasys and Schering-Plough's PegIntron) instead of conventional interferons (i.e., Roche's Roferon and Schering-Plough's Intron A).

As Russia's gross domestic product (GDP) per capita continues to grow, both government and private healthcare spending is expected to increase as well. In 2007, the International Monetary Fund reported government spending on healthcare was only about 3.5 percent of Russia's GDP, but the World Bank and other sources expect this number to increase to 5.5 percent of Russia's GDP by 2013.

The new Emerging Markets report entitled Hepatitis C Virus in Russia also finds that Pegasys and PegIntron will benefit from market growth in Russia. Sales of these two agents will account for 77 percent of the total hepatitis C virus drug market in 2013, an increase from 68 percent in 2008.

"In Russia, Pegasys and PegIntron currently capture a relatively small patient share but have growth potential because physicians and patients perceive them to be more effective and safer than conventional interferons," stated Alexandra Makarova, M.D., Ph.D., analyst at Decision Resources.

The new report is part of an expansion of the Emerging Markets report series to cover Russia. The series contains primary research of physicians and epidemiology study in key pharmaceutical markets of Russia -- Moscow, Saint Petersburg and Novosibirsk.

About Emerging Markets Reports

Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:



Gisselle Morales                             Elizabeth Marshall
Decision Resources                           Decision Resources, Inc.
781-296-2691                                 781-296-2563
gmorales@dresources.com                      emarshall@dresources.com


SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
2. Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine Healive(R)
3. Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
4. Noninvasive Breath Test Predicts Survival in Patients with Viral Hepatitis
5. Difficult-to-Treat Patient Populations Respond Positively to Hepatitis C Treatment
6. Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
7. ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
8. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
9. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
10. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
11. Clinical Update - Debio 025 in Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , February 27, 2017 Now ... the pharmaceutical companies that are most successful at developing and ... ... you gave the same molecule to two different companies in ... Based on systematic, objective analysis of each company,s performance ...
(Date:2/27/2017)... SEATTLE , Feb. 27, 2017  CTI BioPharma Corp. ... of Adam Craig , M.D., Ph.D., as President and ... Directors effective March 20, 2017. Dr. Craig succeeds Richard ... serve on the company,s Board of Directors.  Dr. Craig has ... development in both the US and Europe ...
(Date:2/27/2017)... 2017 The Dutch secure mobile ... use at the security level RESTRICTED. The solution thus meets ... for the communication of classified information. ... Sectra and Samsung have a ... smartphone solution. Sectra Tiger/R is developed by Sectra under guidance ...
Breaking Medicine Technology:
(Date:2/28/2017)... ... February 28, 2017 , ... ... healthcare automation intelligence company based in New York. , “Ensuring an intuitive, user-friendly ... workflow remains unaltered. Those two fundamental reasons are the reasons this acquisition is ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... overall body strength, which often leads to a host of health issues, including ... the American Geriatrics Society discovered that good overall muscle strength in older ...
(Date:2/27/2017)... ... ... The threat of nuclear warfare has long plagued this world. In July ... testing of nuclear weapons. Years later, when her co-workers began dying, Dot started searching ... Testing,” Clayton exposes the critical decisions made by agencies involved in the nuclear testing ...
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines ... despite scientific studies, the Center for Disease Control ( CDC ) and Infectious Diseases ... Kenneth B. Liegner, M.D. has compiled into a single volume a compelling argument that ...
(Date:2/27/2017)... ... , ... New Jersey ranks among the top five states in the entire ... for advanced services is growing. , Project WE vs C is a focused ... their non-profit partners in their fight against cancer and in support of their shared ...
Breaking Medicine News(10 mins):